VevaRX review

A thirty-six-state program selling semaglutide at $189 a month on a page that also prints $167, $399 and $467 for the same drug — and tirzepatide only as a three-month prepay whose advertised per-month equivalent does not divide.

By Grant Ashford, Founder & Pricing EditorSeptember 2026

Est. first month

From $189/mo

Save ~86% vs brand-name

$189/mo month-to-month (or $399 on a three-month prepay; its own page also prints $167 a month and a $467 total)

Get this deal Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Value Score.

Pricing to watch. The semaglutide page carries four prices, and two of them belong to tirzepatide: cards reading $189 a month and $399 for three months, then a paragraph offering a monthly program at $167 or three months at $467. Tirzepatide has no monthly option on its own page at all — only $467 for three months, auto-renewing, with a three-month minimum — and the per-month figure advertised beside it is arithmetically wrong: $467 over three months is $155.67, not the $149 printed. The same disagreement runs through every side product, where the card, the plan text and the cart give three different totals for one item. A separate ladder in the terms matches nothing sold anywhere on the site.

How much does VevaRX cost?

The price VevaRX publishes is $189/mo month-to-month (or $399 on a three-month prepay; its own page also prints $167 a month and a $467 total). We flag this one to watch: confirm the ongoing rate with VevaRX before you count on it, because a low first month can step up afterward. That works out about 86% under our ~$1,349/mo brand-name cash reference.

Semaglutide: $189/mo month-to-month (or $399 on a three-month prepay; its own page also prints $167 a month and a $467 total)
Tirzepatide: $467 per three-month prepay, auto-renewing with a three-month minimum (no monthly rate is published for tirzepatide)
Coverage: 36 states, listed
Brand-name: Compounded only

The Value Score card

VevaRX scored on our six published factors. See the methodology.

Lowest Real Price76/100

No Teaser-Rate Bait40/100

Both Molecules92/100

Nationwide Availability72/100

Easy Cancellation58/100

Reputation75/100

Why it's a deal

The states are published as a named list of thirty-six rather than an all-fifty claim, and the list is the one the site treats as operative
A month-to-month option exists for semaglutide at $189, which is more than the tirzepatide side of the same business offers
The three-month prepay totals are stated as totals — $399 and $467 — rather than only as per-month arithmetic, so the commitment can be priced
Auto-renewal is disclosed plainly on the product pages: the plan renews every three months and can be canceled at any time
A legal entity is published, and side products carry published prices rather than a consultation

Read the fine print

The semaglutide page carries four prices for one drug, and two of them belong to tirzepatide: $189 a month and $399 for three months on the cards, then $167 a month or $467 for three months in the paragraph below them
Tirzepatide is sold only as a three-month prepay at $467 with a three-month minimum, and the per-month equivalent advertised beside it does not divide: $467 over three months is $155.67, not the $149 printed
Every side product publishes three different figures — one on the card, one in the plan text and one in the cart — and in at least one case the card is the wrong one
A third price ladder sits in the terms and matches nothing sold anywhere on the site
Another brand's domain appears in the terms as the site conducting the transactions, and the contact page's questions carry a different product's copy giving dosing instructions for a powdered drink
Two opposite return policies are published: one page says compounded medication that has shipped cannot be returned, another promises results or your money back, and the terms say something different again
No pharmacy is named, no clinician is named, no medical group is named and no 503A or 503B designation appears anywhere across sixteen pages
No street address is published at all, and the only phone number appears in the terms as a text-message keyword rather than a support line

The bottom line

Best for: Readers in one of the thirty-six states listed who will confirm every figure in the cart, since the cards, the plan text and the cart disagree on almost every product. A thirty-six-state program selling semaglutide at $189 a month on a page that also prints $167, $399 and $467 for the same drug — and tirzepatide only as a three-month prepay whose advertised per-month equivalent does not divide.

Ranked #277 of 418 programs we track — see our #1 deal, CoreAge Rx, for comparison.

Get this deal

Compare with other deals

The programs scoring closest to VevaRX, out of 417 others we track.

Shopping VevaRX against a specific rival? We put it head to head with our top-scoring pick on CoreAge Rx vs VevaRX, and every program that undercuts or outscores it — starting with RxPepsDirect, the closest match on score — is ranked on the VevaRX alternatives ranking.

More programs we track (24)

387 more are reviewed too — see every GLP-1 program we track, ranked.

Pricing and coverage on this page were read from VevaRX's own website on September 1, 2026; the Value Score is our editorial judgment per the methodology. “% vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on VevaRX's site. Not medical advice; see our disclosure.

See every program ranked by price →

← Back to all deals